Odd Erik Johansen

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Venues

Diabetes, obesity & metabolism

Nutrients

Metabolites

Diabetes care

Boehringer Ingelheim

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Boehringer Ingelheim Oct 01 2008 - Aug 31 2020

Norway

Sr Medical Director :: Cardiometabolic

Publications

Odd Erik Johansen, Joel Neutel, Sanjay Gupta, Barbara Mariani, Gerhard Ufheil, Emilie Perrin, Andreas Rytz, Anirban Lahiry, Frederik Delodder, Jaclyn Lerea-Antes, Naomi Ocampo, Maximilian von Eynatten
Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People with Obesity, and People with Type 2 Diabetes. Metabolites 14 (8) (2024)
Odd Erik Johansen, Joel Neutel, Sanjay Gupta, Barbara Mariani, Gerhard Ufheil, Emilie Perrin, Andreas Rytz, Anirban Lahiry, Frederik Delodder, Jaclyn Lerea-Antes, Naomi Ocampo, Maximilian von Eynatten
Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People with Obesity, and People with Type 2 Diabetes. Metabolites 14 (8) (2024)
Odd Erik Johansen, Joel Neutel, Sanjay Gupta, Barbara Mariani, Gerhard Ufheil, Emilie Perrin, Andreas Rytz, Anirban Lahiry, Frederik Delodder, Jaclyn Lerea-Antes, Naomi Ocampo, Maximilian von Eynatten
Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People with Obesity, and People with Type 2 Diabetes. Metabolites 14 (8) (2024)
Odd Erik Johansen, Delphine Curti, Maximilian von Eynatten, Andreas Rytz, Anirban Lahiry, Frederik Delodder, Gerhard Ufheil, Carmine D'Urzo, Audrey Orengo, Kate Thorne, Jaclyn S Lerea-Antes
Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial. Nutrients 15 (12) (2023)
Odd Erik Johansen, Delphine Curti, Maximilian von Eynatten, Andreas Rytz, Anirban Lahiry, Frederik Delodder, Gerhard Ufheil, Carmine D'Urzo, Audrey Orengo, Kate Thorne, Jaclyn S Lerea-Antes
Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial. Nutrients 15 (12) (2023)
Odd Erik Johansen, Delphine Curti, Maximilian von Eynatten, Andreas Rytz, Anirban Lahiry, Frederik Delodder, Gerhard Ufheil, Carmine D'Urzo, Audrey Orengo, Kate Thorne, Jaclyn S Lerea-Antes
Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial. Nutrients 15 (12) (2023)
Mafauzy Mohamed, Roberto Luís Zagury, Kalpana Bhaskaran, Joel Neutel, Barakatun Nisak Mohd Yusof, Linda Mooney, Lihe Yeo, Bridget-Anne Kirwan, Olivier Aprikian, Maximilian von Eynatten, Odd Erik Johansen
A Randomized, Placebo-Controlled Crossover Study to Evaluate Postprandial Glucometabolic Effects of Mulberry Leaf Extract, Vitamin D, Chromium, and Fiber in People with Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Jamy D Ard, Ian J Neeland, Amy E Rothberg, Robert J Chilton, Daniel de Luis, Sarah S Cohen, Odd Erik Johansen
The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study. Diabetes, obesity & metabolism (2023)
Jiří Vosáhlo, Adam Salus, Michael Smolko, Barbora Němcová, Veit Nordmeyer, Milos Mikles, Stefanie M Rau, Odd Erik Johansen
Oral enzyme combination with bromelain, trypsin and the flavonoid rutoside reduces systemic inflammation and pain when used pre- and post-operatively in elective total hip replacement: a randomized exploratory placebo-controlled trial. Therapeutic advances in musculoskeletal disease 15 (2023)
Varun Kumar Vijayakumar, Tehmina Mustafa, Bjarte Kjell Nore, Kjell Yngvard Garatun-Tjeldstø, Øystein Næss, Odd Erik Johansen, Bernt Bøgvald Aarli
Role of a Digital Clinical Decision-Support System in General Practitioners' Management of COPD in Norway. International journal of chronic obstructive pulmonary disease 16 (2021)
Gisle Langslet, Bernard Zinman, Christoph Wanner, Stefan Hantel, Rosa-Maria Espadero, David Fitchett, Odd Erik Johansen
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®. Diabetes & vascular disease research 17 (6) (2021)
Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Gudrun Wallenstein, Bernard Zinman, Mark A Espeland, Odd Erik Johansen
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia 64 (6) (2021)
Darren K McGuire, Silvio E Inzucchi, Odd Erik Johansen, Julio Rosenstock, Jyothis T George, Nikolaus Marx
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. Journal of pharmaceutical policy and practice 14 (1) (2021)
Qiuhe Ji, Linong Ji, Yi-Ming Mu, Jiajun Zhao, Bernard Zinman, Christoph Wanner, Jyothis T George, Isabella Zwiener, Kohjiro Ueki, Koutaro Yokote, Wataru Ogawa, Odd Erik Johansen
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia. Diabetes, obesity & metabolism 23 (8) (2021)
Catherine M Viscoli, Melanie Jane Davies, Kamlesh Khunti F MedSci, Prabhav Trivedi, Jyothis T George, Isabella Zwiener, Odd Erik Johansen, Naveed Sattar
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. Diabetes, obesity & metabolism 23 (2) (2020)
Mark E Cooper, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Christoph Wanner, Sven Schnaidt, Douglas Clark, Odd Erik Johansen, null null
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial. Diabetes, obesity & metabolism 22 (7) (2020)
Vlado Perkovic, Robert Toto, Mark E Cooper, Johannes F E Mann, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Nikolaus Marx, John H Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T George, Odd Erik Johansen, Christoph Wanner, null null
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes care 43 (8) (2020)
Mark A Espeland, Richard E Pratley, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Bernard Zinman, Nikolaus Marx, Darren K McGuire, Knut Robert Andersen, Michaela Mattheus, Annett Keller, Maria Weber, Odd Erik Johansen
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes, obesity & metabolism 23 (2) (2020)
Darren K McGuire, Nikolaus Marx, Odd Erik Johansen, Silvio E Inzucchi, Julio Rosenstock, Jyothis T George
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later. Diabetes, obesity & metabolism 21 (5) (2019)
Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Bernard Zinman, Julio Rosenstock, Jyothis T George, Anna Passera, Sven Schnaidt, Odd Erik Johansen, null null
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes care 42 (10) (2019)

Odd Erik Johansen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Odd Erik Johansen